Please assess the completion status of the following clinical trial:

Trial Title: Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* T1D ≥ 2 years~* Use of insulin pump therapy (without sensor-augmented insulin suspension/adjustment functionality) ≥ 6 months~* Use of CGM (real-time or intermittently scanned) ≥ 3 months and ≥ 70% during the previous 14 days~* HbA1c ≤ 70 mmol/l (8.5%)~* Performs aerobic exercise on a regular basis (≥ 2 times per week; self-reported) and desires to exercise per American Diabetes Association guidelines (150 minutes per week) during the study.~* Use of carbohydrate counting and bolus calculator (self-reported)~* Sensor glucose level \< 3.9 mmol/l on ≥ 4/14 previous days assessed by CGM data~Exclusion Criteria:~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start~* Known or suspected allergies to glucagon or related products~* History of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients~* Patients with pheochromocytoma or insulinoma~* Hypoglycemia unawareness~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods~* Inability to understand the individual information and to give informed consent~* Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject~* Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: NO_INTERVENTION): During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
- Dasiglucagon (Type: EXPERIMENTAL): During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).